4,340
Views
7
CrossRef citations to date
0
Altmetric
Review

Distribution and antifungal susceptibility pattern of Candida species from mainland China: A systematic analysis

, , , , , & show all
Pages 1573-1589 | Received 07 May 2022, Accepted 07 Sep 2022, Published online: 18 Sep 2022

References

  • Pfaller MA, Diekema DJ, Turnidge JD, et al. Twenty years of the SENTRY antifungal surveillance program: results for Candida Species from 1997-2016. Open Forum Infect Dis. 2019;6(Suppl 1):S79–S94.
  • Talapko J, Juzbašić M, Matijević T, et al. Candida albicans-The virulence factors and clinical manifestations of infection. J Fungi (Basel). 2021;7(2): DOI:10.3390/jof7020079
  • Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017;17(12):e383–e92.
  • Jeffery-Smith A, Taori SK, Schelenz S, et al. Candida auris: a Review of the Literature. Clin Microbiol Rev. 2018;31(1): DOI:10.1128/CMR.00029-17
  • Guo J, Zhang M, Qiao D, et al. Prevalence and antifungal susceptibility of Candida parapsilosis species complex in Eastern China: a 15-year retrospective study by ECIFIG. Front Microbiol. 2021;12:644000.
  • Chow NA, de Groot T, Badali H, et al. Potential fifth clade of Candida auris, Iran, 2018. Emerg Infect Dis. 2019;25(9):1780–1781.
  • Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of Candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62(4):e1–50.
  • Vaseghi N, Sharifisooraki J, Khodadadi H, et al. Global prevalence and subgroup analyses of coronavirus disease (COVID-19) associated Candida auris infections (CACa): a systematic review and meta-analysis. Mycoses. 2022;65(7):683–703. DOI:10.1111/myc.13471
  • Kollef M, Micek S, Hampton N, et al. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis. 2012;54(12):1739–1746.
  • Chindamporn A, Chakrabarti A, Li R, et al. Survey of laboratory practices for diagnosis of fungal infection in seven Asian countries: an Asia Fungal Working Group (AFWG) initiative. Med Mycol. 2018;56(4):416–425. DOI:10.1093/mmy/myx066
  • Wickes BL, Wiederhold NP. Molecular diagnostics in medical mycology. Nat Commun. 2018;9(1):5135.
  • Amanati A, Badiee P, Jafarian H, et al. Impact of antifungal stewardship interventions on the susceptibility of colonized Candida species in pediatric patients with malignancy. Sci Rep. 2021;11(1):14099. DOI:10.1038/s41598-021-93421-3
  • Kotthoff-Burrell E. Candidemia (blood infection) and other Candida infections. Am J Respir Crit Care Med. 2019;200(5):9–p10.
  • Xiao M, Chen SC, Kong F, et al. Distribution and antifungal susceptibility of candida species causing Candidemia in China: an update from the CHIF-NET study. J Infect Dis. 2020;221(Suppl 2):S139–s47. DOI:10.1093/infdis/jiz573
  • Ziegler A, König IR. Guidelines for research reports: German translation of CONSORT 2010, PRISMA and STARD. Dtsch Med Wochenschr. 2011;136(8):357–358.
  • Wu Y, Li C, Wang Z, et al. Clonal spread and azole-resistant mechanisms of non-susceptible Candida albicans isolates from vulvovaginal candidiasis patients in three Shanghai maternity hospitals. Med Mycol. 2018;56(6):687–694. DOI:10.1093/mmy/myx099
  • Hu L, Du X, Li T, et al. Genetic and phenotypic characterization of Candida albicans strains isolated from infectious disease patients in Shanghai. J Med Microbiol. 2015;64(Pt 1):74–83. DOI:10.1099/jmm.0.080200-0
  • Li F, Wu L, Cao B, et al. Surveillance of the prevalence, antibiotic susceptibility, and genotypic characterization of invasive candidiasis in a teaching hospital in China between 2006 to 2011. BMC Infect Dis. 2013;13:353.
  • Song Y, Chen X, Yan Y, et al. Prevalence and antifungal susceptibility of pathogenic yeasts in China: a 10-year retrospective study in a teaching hospital. Front Microbiol. 2020;11:1401.
  • Zhang W, Song X, Wu H, et al. Epidemiology, species distribution, and predictive factors for mortality of candidemia in adult surgical patients. BMC Infect Dis. 2020;20(1):506.
  • Zheng YJ, Xie T, Wu L, et al. Epidemiology, species distribution, and outcome of nosocomial Candida spp. bloodstream infection in Shanghai: an 11-year retrospective analysis in a tertiary care hospital. Ann Clin Microbiol Antimicrob. 2021;20(1):34. DOI:10.1186/s12941-021-00441-y
  • Wang H, Xiao M, Chen SC, et al. In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study. J Clin Microbiol. 2012;50(12):3952–3959. DOI:10.1128/JCM.01130-12
  • Xiao JL, Xu GC, de Hoog S, et al. Oral prevalence of Candida species in patients undergoing systemic glucocorticoid therapy and the antifungal sensitivity of the isolates. Infect Drug Resist. 2020;13:2601–2607.
  • Wang FJ, Zhang D, Liu ZH, et al. Species distribution and in vitro antifungal susceptibility of Vulvovaginal Candida isolates in China. Chin Med J (Engl). 2016;129(10):1161–1165.
  • Zeng Z, Ding Y, Tian G, et al. A seven-year surveillance study of the epidemiology, antifungal susceptibility, risk factors and mortality of candidaemia among paediatric and adult inpatients in a tertiary teaching hospital in China. Antimicrob Resist Infect Control. 2020;9(1):133. DOI:10.1186/s13756-020-00798-3
  • Yang ZH, Song YG, Li RY. A ten-year retrospective study of invasive Candidiasis in a tertiary hospital in Beijing. Biomed Environ Sci. 2021;34(10):773–788.
  • Pu S, Niu S, Zhang C, et al. Epidemiology, antifungal susceptibilities, and risk factors for invasive candidiasis from 2011 to 2013 in a teaching hospital in southwest China. J Microbiol Immunol Infect. 2017;50(1):97–103. DOI:10.1016/j.jmii.2015.01.005
  • Zeng Z, Tian G, Ding Y, et al. Epidemiology, antifungal susceptibility, risk factors and mortality of invasive candidiasis in neonates and children in a tertiary teaching hospital in Southwest China. Mycoses. 2020;63(11):1164–1174.
  • Xiao Z, Wang Q, Zhu F, et al. Epidemiology, species distribution, antifungal susceptibility and mortality risk factors of candidemia among critically ill patients: a retrospective study from 2011 to 2017 in a teaching hospital in China. Antimicrob Resist Infect Control. 2019;8:89.
  • Zhang W, Song X, Wu H, et al. Epidemiology, risk factors and outcomes of Candida albicans vs. non-albicans candidaemia in adult patients in Northeast China. Epidemiol Infect. 2019;147:e277.
  • Li D, Xia R, Zhang Q, et al. Evaluation of candidemia in epidemiology and risk factors among cancer patients in a cancer center of China: an 8-year case-control study. BMC Infect Dis. 2017;17(1):536.
  • Xiao G, Liao W, Zhang Y, et al. Analysis of fungal bloodstream infection in intensive care units in the Meizhou region of China: species distribution and resistance and the risk factors for patient mortality. BMC Infect Dis. 2020;20(1):599. DOI:10.1186/s12879-020-05291-1
  • Li YY, Chen WY, Li X, et al. Asymptomatic oral yeast carriage and antifungal susceptibility profile of HIV-infected patients in Kunming, Yunnan Province of China. BMC Infect Dis. 2013;13:46.
  • Liu F, Zhong L, Zhou F, et al. Clinical features, strain distribution, antifungal resistance and prognosis of patients with non-albicans Candidemia: a retrospective observational study. Infect Drug Resist. 2021;14:3233–3246.
  • Bai Y, Zheng Z, Liu T, et al. Epidemiological characteristics and drug resistance of Fungemia in general hospitals from 2010 to 2019. Biomed Res Int. 2021;2021:2529171.
  • Zeng ZR, Tian G, Ding YH, et al. Surveillance study of the prevalence, species distribution, antifungal susceptibility, risk factors and mortality of invasive candidiasis in a tertiary teaching hospital in Southwest China. BMC Infect Dis. 2019;19(1):939.
  • Wang H, Liu N, Yin M, et al. The epidemiology, antifungal use and risk factors of death in elderly patients with candidemia: a multicentre retrospective study. BMC Infect Dis. 2014;14:609.
  • Yu SY, Zhang L, Chen S, et al. Candida isolates causing refractory or recurrent oropharyngeal candidiasis in 11 hospitals in China. Infect Drug Resist. 2019;12:865–875.
  • Wang B, He X, Lu F, et al. Candida isolates from blood and other normally sterile Foci from ICU patients: determination of epidemiology, antifungal susceptibility profile and evaluation of associated risk factors. Front Public Health. 2021;9:779590.
  • Luo X, Dong X, Pen Z. Distribution and drug susceptibility of Candida spp. Associated with female genital tract infection, Chongqing, China. Jundishapur J Microbiol. 2016;9(10):e19386.
  • Yang L, Su MQ, Ma YY, et al. Epidemiology, species distribution, antifungal susceptibility, and ERG11 mutations of Candida species isolated from pregnant Chinese Han women. Genet Mol Res. 2016;15(2):1–8.
  • Lin S, Chen R, Zhu S, et al. Candidemia in adults at a tertiary hospital in China: clinical characteristics, species distribution, resistance, and outcomes. Mycopathologia. 2018;183(4):679–689. DOI:10.1007/s11046-018-0258-5
  • Dong D, Li Z, Zhang L, et al. Clinical and microbiological investigation of fungemia from four hospitals in China. Mycopathologia. 2015;179(5–6):407–414. DOI:10.1007/s11046-014-9855-0
  • Pfaller MA, Castanheira M, Messer SA, et al. In vitro antifungal susceptibilities of isolates of Candida spp. And Aspergillus spp. From China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012. Mycoses. 2015;58(4):209–214.
  • Zhang H, Tan J, Kontoyiannis DP, et al. Screening the in vitro susceptibility of posaconazole in clinical isolates of Candida spp. And Aspergillus spp. And analyzing the sequence of ERG11 or CYP51A in non-wild-type isolates from China. Diagn Microbiol Infect Dis. 2019;95(2):166–170. DOI:10.1016/j.diagmicrobio.2019.05.003
  • Liu XP, Fan SR, Peng YT, et al. Species distribution and susceptibility of Candida isolates from patient with vulvovaginal candidiasis in Southern China from 2003 to 2012. Journal de Mycologie Medicale. 2014;24(2):106–111.
  • Ma CF, Li FQ, Shi LN, et al. Surveillance study of species distribution, antifungal susceptibility and mortality of nosocomial candidemia in a tertiary care hospital in China. BMC Infect Dis. 2013;13:337.
  • Guo H, Zhang XL, Gao LQ, et al. Alcohol dehydrogenase I expression correlates with CDR1, CDR2 and FLU1 expression in Candida albicans from patients with vulvovaginal candidiasis. Chin Med J (Engl). 2013;126(11):2098–2102.
  • Ying C, Zhang H, Tang Z, et al. Antifungal susceptibility and molecular typing of 115 Candida albicans isolates obtained from vulvovaginal candidiasis patients in 3 Shanghai maternity hospitals. Med Mycol. 2016;54(4):394–399.
  • Yan L, Wang XD, Seyedmousavi S, et al. Antifungal susceptibility profile of Candida Albicans isolated from Vulvovaginal Candidiasis in Xinjiang Province of China. Mycopathologia. 2019;184(3):413–422. DOI:10.1007/s11046-018-0305-2
  • Wang B, Huang L, Zhao J, et al. ERG11 mutations associated with azole resistance in Candida albicans isolates from vulvovaginal candidosis patients. Asian Pac J Tropical Biomedicine. 2015;5:909–914.
  • Shi C, Liu J, Li W, et al. Expression of fluconazole resistance-associated genes in biofilm from 23 clinical isolates of Candida albicans. Braz J Microbiol. 2019;50(1):157–163.
  • Ying Y, Zhao Y, Hu X, et al. In vitro fluconazole susceptibility of 1,903 clinical isolates of Candida albicans and the identification of ERG11 mutations. Microbial Drug Resist (Larchmont, NY). 2013;19(4):266–273. DOI:10.1089/mdr.2012.0204
  • Liu JY, Shi C, Wang Y, et al. Mechanisms of azole resistance in Candida albicans clinical isolates from Shanghai, China. Res Microbiol. 2015;166(3):153–161.
  • Shi XY, Yang YP, Zhang Y, et al. Molecular identification and antifungal susceptibility of 186 Candida isolates from vulvovaginal candidiasis in southern China. J Med Microbiol. 2015;64(Pt 4):390–393. DOI:10.1099/jmm.0.000024
  • Feng W, Yang J, Ji Y, et al. Mrr2 mutations and upregulation are associated with increased fluconazole resistance in Candida albicans isolates from patients with vulvovaginal candidiasis. Lett Appl Microbiol. 2020;70(2):95–101. DOI:10.1111/lam.13248
  • Feng W, Yang J, Xi Z, et al. Mutations and/or Overexpressions of ERG4 and ERG11 genes in clinical Azoles-Resistant isolates of Candida albicans. Microbial Drug Resist (Larchmont, NY). 2017;23(5):563–570. DOI:10.1089/mdr.2016.0095
  • Xu H, Liu M, Chen Y, et al. Randomly amplified polymorphic deoxyribonucleic acid (DNA) analysis of Candida albicans isolates from clinical sources of hospital in south China. Afr J Microbiol Res. 2012;6(10): 2552–2558.
  • Zhang L, Yang HF, Liu YY, et al. Reduced susceptibility of Candida albicans clinical isolates to azoles and detection of mutations in the ERG11 gene. Diagn Microbiol Infect Dis. 2013;77(4):327–329.
  • Feng W, Yang J, Xi Z, et al. Regulatory role of ERG3 and Efg1 in Azoles-Resistant strains of Candida albicans isolated from patients diagnosed with Vulvovaginal Candidiasis. Indian J Microbiol. 2019;59(4):514–524. DOI:10.1007/s12088-019-00833-x
  • Feng W, Yang J, Yang L, et al. Research of Mrr1, Cap1 and MDR1 in Candida albicans resistant to azole medications. Exp Ther Med. 2018;15(2):1217–1224. DOI:10.3892/etm.2017.5518
  • Tang Y, Yu F, Huang L, et al. The changes of antifungal susceptibilities caused by the phenotypic switching of Candida species in 229 patients with vulvovaginal candidiasis. J Clin Lab Anal. 2019;33(1):e22644.
  • Li HM, Shimizu-Imanishi Y, Tanaka R, et al. White-Opaque switching in different mating type-like locus gene types of clinical Candida albicans Isolates. Chin Med J (Engl). 2016;129(22):2725–2732.
  • Yang ZT, Wu L, Liu XY, et al. Epidemiology, species distribution and outcome of nosocomial Candida spp. bloodstream infection in Shanghai. BMC Infect Dis. 2014;14:241.
  • Chen J, Hu N, Xu H, et al. Molecular epidemiology, antifungal susceptibility, and virulence evaluation of Candida isolates causing invasive infection in a tertiary care teaching hospital. Front Cell Infect Microbiol. 2021;11:721439.
  • Zhu Y, Shan Y, Fan S, et al. Candida parapsilosis sensu stricto and the closely related species Candida orthopsilosis and Candida metapsilosis in vulvovaginal candidiasis. Mycopathologia. 2015;179(1–2):111–118.
  • Zhai Y, Liu J, Zhou L, et al. Detection of Candida species in pregnant Chinese women with a molecular beacon method. J Med Microbiol. 2018;67(6):783–789. DOI:10.1099/jmm.0.000740
  • Guo LN, Yu SY, Xiao M, et al. Species distribution and antifungal susceptibility of invasive Candidiasis: a 2016-2017 multicenter surveillance study in Beijing, China. Infect Drug Resist. 2020;13:2443–2452.
  • Li W, Hu YA, Li FQ, et al. Distribution of yeast isolates from invasive infections and their in vitro susceptibility to antifungal agents: evidence from 299 cases in a 3-year (2010 to 2012) surveillance study. Mycopathologia. 2015;179(5–6):397–405. DOI:10.1007/s11046-015-9858-5
  • Guo LN, Xiao M, Cao B, et al. Epidemiology and antifungal susceptibilities of yeast isolates causing invasive infections across urban Beijing, China. Future Microbiol. 2017;12:1075–1086.
  • Shi Y, Zhu Y, Fan S, et al. Molecular identification and antifungal susceptibility profile of yeast from vulvovaginal candidiasis. BMC Infect Dis. 2020;20(1):287.
  • Zhang L, Zhou S, Pan A, et al. Surveillance of antifungal susceptibilities in clinical isolates of Candida species at 36 hospitals in China from 2009 to 2013. Int J Infect Dis. 2015;33:1–4.
  • Xu H, Yu SY, Zhou ML, et al. Epidemiology and antifungal susceptibility patterns of invasive fungal infections from 2012 to 2014 in a teaching hospital in central China. Infect Drug Resist. 2019;12:3641–3651.
  • Shan Y, Fan S, Liu X, et al. Prevalence of Candida albicans-closely related yeasts, Candida africana and Candida dubliniensis, in vulvovaginal candidiasis. Med Mycol. 2014;52(6):636–640.
  • Wu J, Guo H, Yi G, et al. Prevalent drug resistance among oral yeasts from asymptomatic patients in Hainan, China. Mycopathologia. 2014;177(5–6):299–307. DOI:10.1007/s11046-014-9747-3
  • Zeng X, Peng M, Liu G, et al. Strain distribution and drug susceptibility of invasive fungal infection in clinical patients with systemic internal diseases. Front Bioeng Biotechnol. 2020;8:625024.
  • Zhang JY, Liu JH, Liu FD, et al. Vulvovaginal candidiasis: species distribution, fluconazole resistance and drug efflux pump gene overexpression. Mycoses. 2014;57(10):584–591. DOI:10.1111/myc.12204
  • Wu J, Gan C, Li J, et al. Species diversity and antifungal susceptibilities of oral yeasts from patients with head and neck cancer. Infect Drug Resist. 2021;14:2279–2288.
  • Xiao M, Sun ZY, Kang M, et al. Five-Year national surveillance of invasive Candidiasis: species distribution and Azole susceptibility from the China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study. J Clin Microbiol. 2018;56(7): DOI:10.1128/JCM.00577-18
  • Xiao M, Fan X, Chen SC, et al. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance. J Antimicrob Chemother. 2015;70(3):802–810. DOI:10.1093/jac/dku460
  • Wang D, An N, Yang Y, et al. Candida tropicalis distribution and drug resistance is correlated with ERG11 and UPC2 expression. Antimicrob Resist Infect Control. 2021;10(1):54.
  • Wang Y, Fan X, Wang H, et al. Continual decline in Azole susceptibility rates in Candida tropicalis over a 9-year period in China. Front Microbiol. 2021;12:702839.
  • Jin L, Cao Z, Wang Q, et al. MDR1 overexpression combined with ERG11 mutations induce high-level fluconazole resistance in Candida tropicalis clinical isolates. BMC Infect Dis. 2018;18(1):162. DOI:10.1186/s12879-018-3082-0
  • Jiang C, Dong D, Yu B, et al. Mechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in China. J Antimicrob Chemother. 2013;68(4):778–785. DOI:10.1093/jac/dks481
  • Wang Q, Li C, Tang D, et al. Molecular epidemiology of Candida tropicalis isolated from urogenital tract infections. Microbiologyopen. 2020;9(11):e1121.
  • Fan X, Xiao M, Zhang D, et al. Molecular mechanisms of azole resistance in Candida tropicalis isolates causing invasive candidiasis in China. Clin Microbiol Infect. 2019;25(7):885–891. DOI:10.1016/j.cmi.2018.11.007
  • Fan X, Xiao M, Wang H, et al. Multilocus sequence typing indicates diverse origins of invasive Candida tropicalis isolates in China. Chin Med J (Engl). 2014;127(24):4226–4234.
  • Wang Q, Tang D, Tang K, et al. Multilocus sequence typing reveals clonality of Fluconazole-Nonsusceptible Candida tropicalis: a Study from Wuhan to the Global. Front Microbiol. 2020;11:554249.
  • Fan X, Xiao M, Liao K, et al. Notable increasing trend in Azole non-susceptible Candida tropicalis causing invasive Candidiasis in China (August 2009 to July 2014): molecular epidemiology and clinical Azole consumption. Front Microbiol. 2017;8:464.
  • Hou X, Xiao M, Wang H, et al. Profiling of PDR1 and MSH2 in Candida glabrata bloodstream isolates from a multicenter study in China. Antimicrob Agents Chemother. 2018;62(6): DOI:10.1128/AAC.00153-18
  • Yang W, Ji X. Analysis of the microbial species, antimicrobial sensitivity and drug resistance in 2652 patients of nursing hospital. Heliyon. 2020;6(5):e03965.
  • Yao D, Chen J, Chen W, et al. Mechanisms of azole resistance in clinical isolates of Candida glabrata from two hospitals in China. Infect Drug Resist. 2019;12:771–781.
  • Hou X, Xiao M, Chen SC, et al. Molecular epidemiology and antifungal susceptibility of Candida glabrata in China (August 2009 to July 2014): a multi-center study. Front Microbiol. 2017;8:880.
  • Liu Y, Kang M, Ye H, et al. Analysis on clinical characteristics and drug resistance of Candida parapsilosis bloodstream infections in West China Hospital, China, from 2012 to 2015. Journal de Mycologie Medicale. 2018;28(1):222–226.
  • Zhang L, Yu SY, Chen SC, et al. Molecular Characterization of Candida parapsilosis by microsatellite typing and emergence of clonal antifungal drug resistant strains in a multicenter surveillance in China. Front Microbiol. 2020;11:1320.
  • Feng W, Yang J, Wang Y, et al. ERG11 mutations and upregulation in clinical itraconazole-resistant isolates of Candida krusei. Can J Microbiol. 2016;62(11):938–943.
  • Gong J, Xiao M, Wang H, et al. Genetic differentiation, diversity, and drug susceptibility of Candida krusei. Front Microbiol. 2018;9:2717.
  • Cheng JW, Yu SY, Xiao M, et al. Identification and antifungal susceptibility profile of Candida guilliermondii and Candida fermentati from a multicenter study in China. J Clin Microbiol. 2016;54(8):2187–2189. DOI:10.1128/JCM.00938-16
  • Cheng JW, Liao K, Kudinha T, et al. Molecular epidemiology and azole resistance mechanism study of Candida guilliermondii from a Chinese surveillance system. Sci Rep. 2017;7(1):907. DOI:10.1038/s41598-017-01106-7
  • Tian S, Bing J, Chu Y, et al. Genomic epidemiology of Candida auris in a general hospital in Shenyang, China: a three-year surveillance study. Emerging Microbes Infect. 2021;10(1):1088–1096. DOI:10.1080/22221751.2021.1934557
  • Tian S, Rong C, Nian H, et al. First cases and risk factors of super yeast Candida auris infection or colonization from Shenyang, China. Emerging Microbes Infect. 2018;7(1):128. DOI:10.1038/s41426-018-0131-0
  • Hou X, Xiao M, Chen SC, et al. Identification and antifungal susceptibility profiles of Candida haemulonii species complex clinical isolates from a multicenter study in China. J Clin Microbiol. 2016;54(11):2676–2680. DOI:10.1128/JCM.01492-16
  • Mixão V, Gabaldón T. Genomic evidence for a hybrid origin of the yeast opportunistic pathogen Candida albicans. BMC Biol. 2020;18(1):48.
  • Sardi JCO, Scorzoni L, Bernardi T, et al. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol. 2013;62(Pt 1):10–24.
  • Verma R, Pradhan D, Hasan Z, et al. A systematic review on distribution and antifungal resistance pattern of Candida species in the Indian population. Med Mycol. 2021;59(12):1145–1165.
  • Zhang Z, Bai HH, Wang FJ, et al. Analysis of homology and drug sensitivity of vaginal isolates of 10 patients with recurrent vulvovaginal candidiasis in recurrent episodes. Zhonghua Fu Chan Ke Za Zhi. 2020;55(3):177–182. DOI:10.3760/cma.j.cn112141-20191210-00665
  • Pappas PG, Lionakis MS, Arendrup MC, et al. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026.
  • Tsai MH, Hsu JF, Yang LY, et al. Candidemia due to uncommon Candida species in children: new threat and impacts on outcomes. Sci Rep. 2018;8(1):15239. DOI:10.1038/s41598-018-33662-x
  • Chow NA, Gade L, Tsay SV, et al. Multiple introductions and subsequent transmission of multidrug-resistant Candida auris in the USA: a molecular epidemiological survey. Lancet Infect Dis. 2018;18(12):1377–1384. DOI:10.1016/S1473-3099(18)30597-8
  • Afsarian MH, Badali H, Boekhout T, et al. Multilocus sequence typing of Candida albicans isolates from a burn intensive care unit in Iran. J Med Microbiol. 2015;64(Pt 3):248–253.
  • Chapman B, Slavin M, Marriott D, et al. Changing epidemiology of candidaemia in Australia. J Antimicrob Chemother. 2017;72(4):1103–1108. DOI:10.1093/jac/dkx047
  • Lamoth F, Lockhart SR, Berkow EL, et al. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother. 2018;73(suppl_1):i4–i13.
  • Hachem R, Hanna H, Kontoyiannis D, et al. The changing epidemiology of invasive candidiasis: candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer. 2008;112(11):2493–2499.
  • Gupta AK, Venkataraman M. Antifungal resistance in Superficial mycoses. J Dermatolog Treat. 2021;32:1–25.
  • Pristov KE, Ghannoum MA. Resistance of Candida to azoles and echinocandins worldwide. Clin Microbiol Infect. 2019;25(7):792–798.
  • Whaley SG, Berkow EL, Rybak JM, et al. Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species. Front Microbiol. 2016;7:2173.
  • Corcione S, D’Avolio A, Pasero D, et al. Acquisition of FKS2 mutation after echinocandin treatment of infective endocarditis by Candida glabrata. Le Infezioni in Medicina. 2019;27(3):328–331.
  • Forsberg K, Woodworth K, Walters M, et al. Candida auris: the recent emergence of a multidrug-resistant fungal pathogen. Med Mycol. 2019;57(1):1–12. DOI:10.1093/mmy/myy054
  • Alastruey-Izquierdo A, Melhem MS, Bonfietti LX, et al. Susceptibility test for fungi: clinical and laboratorial correlations in medical mycology. Rev Inst Med Trop Sao Paulo. 2015;57 Suppl 19(Suppl 19):57–64.
  • Badiee P, Badali H, Boekhout T, et al. Antifungal susceptibility testing of Candida species isolated from the immunocompromised patients admitted to ten university hospitals in Iran: comparison of colonizing and infecting isolates. BMC Infect Dis. 2017;17(1):727. DOI:10.1186/s12879-017-2825-7
  • Briano F, Magnasco L, Sepulcri C, et al. Candida auris Candidemia in critically Ill, colonized patients: cumulative incidence and risk factors. Infect Dis Ther. 2022;11(3):1149–1160. DOI:10.1007/s40121-022-00625-9
  • Lau AF, Kabir M, Chen SC, et al. Candida colonization as a risk marker for invasive candidiasis in mixed medical-surgical intensive care units: development and evaluation of a simple, standard protocol. J Clin Microbiol. 2015;53(4):1324–1330. DOI:10.1128/JCM.03239-14
  • Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr. 2016;4(2). DOI:10.1128/microbiolspec.VMBF-0016-2015
  • Sjölund M, Bonnedahl J, Hernandez J, et al. Dissemination of multidrug-resistant bacteria into the Arctic. Emerg Infect Dis. 2008;14(1):70–72. DOI:10.3201/eid1401.070704
  • Dynowska M, Ejdys E, Biedunkiewicz A, et al. Yeasts isolated from frequently in-patients and out-patients. Ann Parasitol. 2014;60(3):199–206.
  • Diallo OO, Baron SA, Abat C, et al. Antibiotic resistance surveillance systems: a review. J Glob Antimicrob Resist. 2020;23:430–438.